Muqit Mahiul M K, Marcellino George R, Henson David B, Young Lorna B, Patton Niall, Charles Stephen J, Turner George S, Stanga Paulo E
University of Manchester, Manchester Royal Eye Hospital, Oxford Road, Manchester M139WH, England.
Arch Ophthalmol. 2010 May;128(5):525-33. doi: 10.1001/archophthalmol.2010.60.
To investigate the effects of pattern scanning laser (Pascal; OptiMedica, Santa Clara, California) multispot panretinal photocoagulation given in a single-session (SS-PRP) vs single-spot multiple-session PRP (MS-PRP) on proliferative diabetic retinopathy (PDR).
Single-center, randomized clinical trial of 40 eyes. Proliferative diabetic retinopathy was treated with a 400-mum spot size in 1500 burns given either as Pascal in 20-millisecond SS-PRP or in 3 sessions (100-millisecond MS-PRP) during a 4-week period. Visual acuity, central subfield retinal thickness (CRT), and 24-2 Swedish interactive thresholding algorithm visual fields were recorded at baseline and 4 and 12 weeks.
Central subfield retinal thickness, mean deviation, and PDR grade at 12 weeks.
There was a significant increase in mean CRT with MS-PRP (22 mum at 4 weeks, 95% CI, -32.25 to -10.75; 20 mum at 12 weeks, 95% CI, -28.75 to -10.82; P < .001) and no significant increase in the SS-PRP group. The mean deviation increased significantly in the SS-PRP group after 4 weeks (0.73 dB, P = .048), with no significant changes in either group at other points. A positive effect on PDR was observed in 74% of eyes in the SS-PRP group vs 53% in the MS-PRP group (P = .31). Mean treatment time for SS-PRP was 5.04 minutes (SD, 1.5 minutes) compared with 59.3 (SD, 12.7 minutes) in the MS-PRP group (P < .001).
There were no adverse outcomes (CRT, visual acuity, or visual field) from using multispot SS-PRP vs single-spot MS-PRP at 12 weeks postlaser, and treatment times were significantly shorter for multispot SS-PRP. Pascal SS-PRP was as effective as MS-PRP in the treatment of PDR.
Twenty-millisecond Pascal SS-PRP may be safely and rapidly performed in 1500 burns with a similar efficacy to conventional MS-PRP. TRIAL IDENTIFIER: Research and Development Office PIN R00037, Central Manchester University Hospitals Foundation Trust.
研究单次治疗的模式扫描激光（帕斯卡；OptiMedica公司，加利福尼亚州圣克拉拉）多点全视网膜光凝（SS-PRP）与单点多次治疗全视网膜光凝（MS-PRP）对增殖性糖尿病视网膜病变（PDR）的影响。
一项针对40只眼的单中心随机临床试验。增殖性糖尿病视网膜病变采用400微米光斑大小，在1500个光斑处进行治疗，治疗方式为在4周内采用帕斯卡激光进行20毫秒的SS-PRP或分3次进行（100毫秒的MS-PRP）。在基线、4周和12周时记录视力、中心子野视网膜厚度（CRT）和24-2瑞典交互式阈值算法视野。
12周时的中心子野视网膜厚度、平均偏差和PDR分级。
MS-PRP组的平均CRT有显著增加（4周时增加22微米，95%可信区间为-32.25至-10.75；12周时增加20微米，95%可信区间为-28.75至-10.82；P < 0.001），而SS-PRP组无显著增加。SS-PRP组在4周后平均偏差显著增加（0.73 dB，P = 0.048），其他时间点两组均无显著变化。SS-PRP组74%的眼对PDR有积极效果，而MS-PRP组为53%（P = 0.31）。SS-PRP的平均治疗时间为5.04分钟（标准差为1.5分钟），而MS-PRP组为�9.3（标准差为12.7分钟）（P < 0.001）。
激光治疗12周后，使用多点SS-PRP与单点MS-PRP相比，没有不良后果（CRT、视力或视野），且多点SS-PRP的治疗时间明显更短。帕斯卡SS-PRP在治疗PDR方面与MS-PRP效果相同。
20毫秒的帕斯卡SS-PRP可在1500个光斑处安全快速地进行，疗效与传统的MS-PRP相似。试验识别号：曼彻斯特中心大学医院基金会信托研发办公室PIN R00037。
Zotero 插件